Mitchell S. Kapoor
Stock Analyst at HC Wainwright & Co.
(3.63)
# 744
Out of 5,180 analysts
90
Total ratings
40.91%
Success rate
9.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell S. Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Buy | $40 → $25 | $22.03 | +13.48% | 4 | Mar 30, 2026 | |
| INCY Incyte | Reiterates: Buy | $135 | $94.12 | +43.43% | 5 | Mar 30, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $7 | $1.75 | +300.00% | 1 | Mar 26, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $110 → $120 | $75.09 | +59.81% | 7 | Mar 25, 2026 | |
| AVTX Avalo Therapeutics | Maintains: Buy | $25 → $40 | $14.93 | +167.92% | 3 | Mar 25, 2026 | |
| EVMN Evommune | Maintains: Buy | $65 → $50 | $22.99 | +117.49% | 3 | Mar 18, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Buy | $10 → $17 | $4.70 | +261.70% | 2 | Mar 16, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $25 → $30 | $12.82 | +134.01% | 7 | Mar 3, 2026 | |
| CBIO Crescent Biopharma | Maintains: Buy | $25 → $22 | $18.37 | +19.76% | 3 | Mar 2, 2026 | |
| SRPT Sarepta Therapeutics | Reiterates: Sell | $5 | $21.76 | -77.02% | 4 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $55 | $56.49 | -2.64% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $30 | $18.96 | +58.23% | 8 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $45 | $38.30 | +17.49% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $11.33 | +76.52% | 3 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $50 | $18.09 | +176.40% | 2 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $20.16 | +247.22% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $5.74 | +74.22% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.26 | - | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $64.63 | +39.25% | 5 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 → $45 | $20.25 | +122.22% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.66 | +130.95% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $30 | $6.15 | +387.80% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $20 | $8.63 | +131.75% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $40 | $49.05 | -18.45% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $47.57 | +68.17% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.47 | +102.43% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.34 | +422.39% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $5.95 | -66.39% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.11 | +260.36% | 1 | Aug 11, 2025 |
Alumis
Mar 30, 2026
Maintains: Buy
Price Target: $40 → $25
Current: $22.03
Upside: +13.48%
Incyte
Mar 30, 2026
Reiterates: Buy
Price Target: $135
Current: $94.12
Upside: +43.43%
Palisade Bio
Mar 26, 2026
Initiates: Buy
Price Target: $7
Current: $1.75
Upside: +300.00%
Ionis Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $110 → $120
Current: $75.09
Upside: +59.81%
Avalo Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $25 → $40
Current: $14.93
Upside: +167.92%
Evommune
Mar 18, 2026
Maintains: Buy
Price Target: $65 → $50
Current: $22.99
Upside: +117.49%
CytomX Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $10 → $17
Current: $4.70
Upside: +261.70%
Intellia Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $12.82
Upside: +134.01%
Crescent Biopharma
Mar 2, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $18.37
Upside: +19.76%
Sarepta Therapeutics
Mar 2, 2026
Reiterates: Sell
Price Target: $5
Current: $21.76
Upside: -77.02%
Mar 2, 2026
Reiterates: Neutral
Price Target: $55
Current: $56.49
Upside: -2.64%
Feb 24, 2026
Maintains: Buy
Price Target: $40 → $30
Current: $18.96
Upside: +58.23%
Feb 17, 2026
Maintains: Buy
Price Target: $30 → $45
Current: $38.30
Upside: +17.49%
Jan 29, 2026
Upgrades: Buy
Price Target: $20
Current: $11.33
Upside: +76.52%
Jan 22, 2026
Maintains: Buy
Price Target: $60 → $50
Current: $18.09
Upside: +176.40%
Jan 13, 2026
Reiterates: Buy
Price Target: $70
Current: $20.16
Upside: +247.22%
Jan 13, 2026
Maintains: Buy
Price Target: $13 → $10
Current: $5.74
Upside: +74.22%
Jan 7, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.26
Upside: -
Dec 19, 2025
Reiterates: Buy
Price Target: $90
Current: $64.63
Upside: +39.25%
Dec 9, 2025
Upgrades: Buy
Price Target: $20 → $45
Current: $20.25
Upside: +122.22%
Nov 24, 2025
Initiates: Buy
Price Target: $20
Current: $8.66
Upside: +130.95%
Nov 19, 2025
Maintains: Buy
Price Target: $40 → $30
Current: $6.15
Upside: +387.80%
Oct 27, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $8.63
Upside: +131.75%
Oct 27, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $49.05
Upside: -18.45%
Sep 23, 2025
Reiterates: Buy
Price Target: $80
Current: $47.57
Upside: +68.17%
Sep 5, 2025
Reiterates: Buy
Price Target: $5
Current: $2.47
Upside: +102.43%
Aug 19, 2025
Reiterates: Buy
Price Target: $7
Current: $1.34
Upside: +422.39%
Aug 19, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $5.95
Upside: -66.39%
Aug 11, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.11
Upside: +260.36%